Girit, SaniyeAtabek, Ayse AyzitSenol, EbruKockar Kizilirmak, TubaPekcan, SevgiGoktas, SafakOktem, Sedat2024-02-232024-02-2320202148-50461309-0283https://doi.org/10.5606/ArchRheumatol.2020.7294https://hdl.handle.net/20.500.12452/17039Objectives: This study aims to analyze the coherence between T-SPOT tuberculosis test (T-SPOT.TB) and tuberculin skin test (TST) with different cut-off values in screening latent tuberculosis infection (LTBI) both prior to and at the sixth month of anti-tumor necrosis factor (anti-TNF) treatment. Patients and methods: This prospective multicentric study included 57 children (34 girls, 23 boys, mean age 12.4 +/- 3.9 years; range, 6 to 18 years) diagnosed with immune-mediated inflammatory diseases (IMIDs) evaluated with TST and T-SPOT.TB for screening LTBI both prior to and at the sixth month of treatment with anti-TNF agents. Coherence between two tests was analyzed for TST cut-off values suggested by the local guidelines and also for different possible cut-off values of TST. Results: Tuberculin skin test was positive (>= 5 mm) in 28.1% (n=16) of patients in the screening prior to treatment and in 33.3% (n=19) at the sixth month of treatment. T-SPOT.TB test was positive in 8.8% (n=5) of patients both prior to and at the sixth month of treatment. Coherence between two tests was poor or fair when compared with all possible TST cut-off values both prior to and at the sixth month of anti-TNF therapy. Conclusion: Our results show poor coherence between T-SPOT.TB and TST for all possible cut- off values of TST. Thus, using both tests would be beneficial in screening LTBI until further studies bring new evidence on the subject.eninfo:eu-repo/semantics/openAccessChildImmune System DiseaseInterferon-Gamma Release AssayLatent TuberculosisTuberculin Skin TestArticle3512028326379162-s2.0-85088380238Q4WOS:000520407500004Q410.5606/ArchRheumatol.2020.7294